BUZZ- Intellipharmaceutics International Inc: Analyst downgrades to "Hold"
** Canada-based drugmaker's U.S.-listed shares down 12 percent at $2.97
** Maxim Group analysts downgrades stock to "hold" from "buy" and cuts price target to $3 from $7, saying second-quarter revenue missed their expectations and costs exceeded estimates
** Analysts also concerns about revenue assumptions from Intellipharmaceutics' generic version of Novartis Pharmaceuticals Corp's drug Focalin XR
© Thomson Reuters 2017 All rights reserved.